Cargando…
Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid
The Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) was introduced for classifying suspected hepatocellular carcinoma (HCC). However, it cannot be applied to Sonazoid. We assessed the diagnostic usefulness of a modified CEUS LI-RADS for HCC and non-HCC malignancie...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602639/ https://www.ncbi.nlm.nih.gov/pubmed/33076435 http://dx.doi.org/10.3390/diagnostics10100828 |
_version_ | 1783603729601134592 |
---|---|
author | Sugimoto, Katsutoshi Kakegawa, Tatsuya Takahashi, Hiroshi Tomita, Yusuke Abe, Masakazu Yoshimasu, Yu Takeuchi, Hirohito Kasai, Yoshitaka Itoi, Takao |
author_facet | Sugimoto, Katsutoshi Kakegawa, Tatsuya Takahashi, Hiroshi Tomita, Yusuke Abe, Masakazu Yoshimasu, Yu Takeuchi, Hirohito Kasai, Yoshitaka Itoi, Takao |
author_sort | Sugimoto, Katsutoshi |
collection | PubMed |
description | The Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) was introduced for classifying suspected hepatocellular carcinoma (HCC). However, it cannot be applied to Sonazoid. We assessed the diagnostic usefulness of a modified CEUS LI-RADS for HCC and non-HCC malignancies based on sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Patients with chronic liver disease at risk for HCC were evaluated retrospectively. Nodules ≥1 cm with arterial phase hyperenhancement, no early washout (within 60 s), and contrast defects in the Kupffer phase were classified as LR-5. Nodules showing early washout, contrast defects in the Kupffer phase, and/or rim enhancement were classified as LR-M. A total of 104 nodules in 104 patients (median age: 70.0 years; interquartile range: 54.5–78.0 years; 74 men) were evaluated. The 48 (46.2%) LR-5 lesions included 45 HCCs, 2 high-flow hemangiomas, and 1 adrenal rest tumor. The PPV of LR-5 for HCC was 93.8% (95% confidence interval (CI): 82.8–98.7%). The 22 (21.2%) LR-M lesions included 16 non-HCC malignancies and 6 HCCs. The PPV of LR-M for non-HCC malignancies, including six intrahepatic cholangiocarcinomas, was 100% (95% CI: 69.8–100%). In conclusion, in the modified CEUS LI-RADS for Sonazoid, LR-5 and LR-M are good predictors of HCC and non-HCC malignancies, respectively. |
format | Online Article Text |
id | pubmed-7602639 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76026392020-11-01 Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid Sugimoto, Katsutoshi Kakegawa, Tatsuya Takahashi, Hiroshi Tomita, Yusuke Abe, Masakazu Yoshimasu, Yu Takeuchi, Hirohito Kasai, Yoshitaka Itoi, Takao Diagnostics (Basel) Article The Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) was introduced for classifying suspected hepatocellular carcinoma (HCC). However, it cannot be applied to Sonazoid. We assessed the diagnostic usefulness of a modified CEUS LI-RADS for HCC and non-HCC malignancies based on sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). Patients with chronic liver disease at risk for HCC were evaluated retrospectively. Nodules ≥1 cm with arterial phase hyperenhancement, no early washout (within 60 s), and contrast defects in the Kupffer phase were classified as LR-5. Nodules showing early washout, contrast defects in the Kupffer phase, and/or rim enhancement were classified as LR-M. A total of 104 nodules in 104 patients (median age: 70.0 years; interquartile range: 54.5–78.0 years; 74 men) were evaluated. The 48 (46.2%) LR-5 lesions included 45 HCCs, 2 high-flow hemangiomas, and 1 adrenal rest tumor. The PPV of LR-5 for HCC was 93.8% (95% confidence interval (CI): 82.8–98.7%). The 22 (21.2%) LR-M lesions included 16 non-HCC malignancies and 6 HCCs. The PPV of LR-M for non-HCC malignancies, including six intrahepatic cholangiocarcinomas, was 100% (95% CI: 69.8–100%). In conclusion, in the modified CEUS LI-RADS for Sonazoid, LR-5 and LR-M are good predictors of HCC and non-HCC malignancies, respectively. MDPI 2020-10-15 /pmc/articles/PMC7602639/ /pubmed/33076435 http://dx.doi.org/10.3390/diagnostics10100828 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sugimoto, Katsutoshi Kakegawa, Tatsuya Takahashi, Hiroshi Tomita, Yusuke Abe, Masakazu Yoshimasu, Yu Takeuchi, Hirohito Kasai, Yoshitaka Itoi, Takao Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid |
title | Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid |
title_full | Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid |
title_fullStr | Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid |
title_full_unstemmed | Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid |
title_short | Usefulness of Modified CEUS LI-RADS for the Diagnosis of Hepatocellular Carcinoma Using Sonazoid |
title_sort | usefulness of modified ceus li-rads for the diagnosis of hepatocellular carcinoma using sonazoid |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602639/ https://www.ncbi.nlm.nih.gov/pubmed/33076435 http://dx.doi.org/10.3390/diagnostics10100828 |
work_keys_str_mv | AT sugimotokatsutoshi usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT kakegawatatsuya usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT takahashihiroshi usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT tomitayusuke usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT abemasakazu usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT yoshimasuyu usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT takeuchihirohito usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT kasaiyoshitaka usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid AT itoitakao usefulnessofmodifiedceusliradsforthediagnosisofhepatocellularcarcinomausingsonazoid |